Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

[Clinical pharmacists in palliative care: effects on drug therapy and drug expenses].

Wolf C, Dörje F, Klein C, Ostgathe C.

Schmerz. 2019 Aug 28. doi: 10.1007/s00482-019-00405-4. [Epub ahead of print] German.

PMID:
31463583
2.

Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety.

Grafe C, Semrau S, Hein A, Beckmann MW, Mackensen A, Dörje F, Fromm MF.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Feb;391(2):219-229. doi: 10.1007/s00210-017-1456-2. Epub 2018 Jan 2.

PMID:
29294142
3.

Advances in clinical pharmacy education in Germany: a quasi-experimental single-blinded study to evaluate a patient-centred clinical pharmacy course in psychiatry.

Dircks M, Mayr A, Freidank A, Kornhuber J, Dörje F, Friedland K.

BMC Med Educ. 2017 Dec 12;17(1):251. doi: 10.1186/s12909-017-1092-z.

4.

[HERA-QUEST: HTA evaluation of generic pharmaceutical products to improve quality, economic efficiency, patient safety and transparency in drug product changes in hospitals].

Gyalrong-Steur M, Kellermann A, Bernard R, Berndt G, Bindemann M, Nusser-Rothermundt E, Amann S, Brakebusch M, Brüggmann J, Tydecks E, Müller M, Dörje F, Kochs E, Riedel R.

Z Evid Fortbild Qual Gesundhwes. 2017 Apr;121:5-13. doi: 10.1016/j.zefq.2017.01.002. Epub 2017 Feb 9. German.

PMID:
28545614
5.

Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting.

Zaloga J, Pöttler M, Leitinger G, Friedrich RP, Almer G, Lyer S, Baum E, Tietze R, Heimke-Brinck R, Mangge H, Dörje F, Lee G, Alexiou C.

Eur J Pharm Biopharm. 2016 Apr;101:152-62. doi: 10.1016/j.ejpb.2016.01.017. Epub 2016 Feb 8.

PMID:
26854862
6.

Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility.

Zaloga J, Janko C, Nowak J, Matuszak J, Knaup S, Eberbeck D, Tietze R, Unterweger H, Friedrich RP, Duerr S, Heimke-Brinck R, Baum E, Cicha I, Dörje F, Odenbach S, Lyer S, Lee G, Alexiou C.

Int J Nanomedicine. 2014 Oct 20;9:4847-66. doi: 10.2147/IJN.S68539. eCollection 2014.

7.

Palliative treatment of colorectal cancer with secondary metastasis resection in Germany - impact of the multidisciplinary treatment approach on prognosis and cost: the Northern Bavaria IVOPAK I Project.

Wein A, Emmert M, Merkel S, Harich HD, Siebler J, Thiemann R, Lamberti C, Göttler B, Fries S, Kiani A, Schlag R, Grüner M, Steinbild S, Eberl S, Pohl-Dernick K, Dörje F, Horbach T, Schöffski O, Neurath MF, Hohenberger W.

Oncology. 2015;88(2):103-21. doi: 10.1159/000368246. Epub 2014 Oct 17.

8.

Intensified pharmaceutical care is improving immunosuppressive medication adherence in kidney transplant recipients during the first post-transplant year: a quasi-experimental study.

Joost R, Dörje F, Schwitulla J, Eckardt KU, Hugo C.

Nephrol Dial Transplant. 2014 Aug;29(8):1597-607. doi: 10.1093/ndt/gfu207. Epub 2014 Jun 9.

PMID:
24914089
9.

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease.

Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, Willma M, App C, Münster T, Kessler H, Maas S, Gebhardt B, Heimke-Brinck R, Reuter E, Dörje F, Rau TT, Uter W, Wang TD, Kiesslich R, Vieth M, Hannappel E, Neurath MF.

Nat Med. 2014 Mar;20(3):313-8. doi: 10.1038/nm.3462. Epub 2014 Feb 23.

10.

Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.

Koch S, Wein A, Siebler J, Boxberger F, Neurath MF, Harich HD, Hohenberger W, Dörje F.

Support Care Cancer. 2013 Sep;21(9):2395-402. doi: 10.1007/s00520-013-1801-z. Epub 2013 Apr 9.

PMID:
23568765
11.

Preventive counselling for public health in pharmacies in South Germany.

Schmiedel K, Schlager H, Dörje F.

Int J Clin Pharm. 2013 Feb;35(1):138-44. doi: 10.1007/s11096-012-9722-3. Epub 2012 Nov 6.

PMID:
23129420
12.

Palliative treatment of colorectal cancer in Germany: cost of care and quality of life.

Emmert M, Pohl-Dernick K, Wein A, Dörje F, Merkel S, Boxberger F, Männlein G, Joost R, Harich HD, Thiemann R, Lamberti C, Neurath MF, Hohenberger W, Schöffski O.

Eur J Health Econ. 2013 Aug;14(4):629-38. doi: 10.1007/s10198-012-0408-5. Epub 2012 Jun 12.

PMID:
22688440
13.

Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.

Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, Dörje F, Mürdter TE, Ackermann A, Dormann H, Gassmann KG, Hahn EG, Zierhut S, Brune K, Fromm MF.

Clin Pharmacokinet. 2007;46(12):1039-49.

PMID:
18027988
14.

The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3.

Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, Dörje F, Fromm MF, König J.

Drug Metab Dispos. 2007 May;35(5):779-86. Epub 2007 Feb 12.

PMID:
17296622
15.

Hospital use of systemic antifungal drugs.

de With K, Steib-Bauert M, Knoth H, Dörje F, Strehl E, Rothe U, Maier L, Kern WV.

BMC Clin Pharmacol. 2005 Feb 10;5:1.

16.

Antibiotic use in German university hospitals 1998-2000 (Project INTERUNI-II).

de With K, Bergner J, Bühner R, Dörje F, Gonnermann C, Haber M, Hartmann M, Rothe U, Strehl E, Steib-Bauert M, Kern WV.

Int J Antimicrob Agents. 2004 Sep;24(3):213-8.

PMID:
15325423
17.

[Antibiotic Use at German University Hospitals (Project INTERUNI-II). Results for Medical Intensive Care, Hematology-Oncology, and Other Medical Service Areas].

de With K, Bergner J, Bühner R, Dörje F, Gonnermann C, Haber M, Hartmann M, Rothe U, Strehl E, Steib-Bauert M, Kern WV.

Med Klin (Munich). 2004 Jul 15;99(7):347-54. German.

PMID:
15322713
18.

Update on glycopeptide use in german university hospitals.

Kern WV, De With K, Gonnermann C, Strehl E, Bergner J, Höffken G, Dörje F, Daschner F, Steib-Bauert M, Haber M, Herrmann M, Hartmann M, Straube E, Bühner R, Rothe U, Salzberger B, Marre R, Kern P; Medical Antibiotic Use Surveillance and Evaluation.

Infection. 2004 Jun;32(3):157-62.

PMID:
15188076
19.

Effect of extracellular calcium concentration on potency of muscarinic agonists at M1 and M2 receptors in rabbit vas deferens.

Dörje F, Rettenmayr NM, Mutschler E, Lambrecht G.

Eur J Pharmacol. 1991 Oct 22;203(3):417-20.

PMID:
1723047
20.

Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues.

Dörje F, Levey AI, Brann MR.

Mol Pharmacol. 1991 Oct;40(4):459-62.

PMID:
1921982
21.

Antagonist binding profiles of five cloned human muscarinic receptor subtypes.

Dörje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR.

J Pharmacol Exp Ther. 1991 Feb;256(2):727-33.

PMID:
1994002
22.
23.
24.

Novel pharmacological profile of muscarinic receptors mediating contraction of the guinea-pig uterus.

Dörje F, Friebe T, Tacke R, Mutschler E, Lambrecht G.

Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):284-9.

PMID:
2280796

Supplemental Content

Support Center